ARTICLE | Clinical News
Buprenorphine Sublingual Spray: Phase III data
September 5, 2016 7:00 AM UTC
Top-line data from a double-blind, U.S. Phase III trial in 322 patients with moderate to severe postoperative pain after a bunionectomy showed that thrice-daily 0.125, 0.25 and 0.5 mg Buprenorphine Su...